1816 Preliminary Safety Results from PERUSE, a Study of 1436 Patients (pts) Treated with First-Line Pertuzumab (P) Combined with Trastuzumab (H) and Taxane Therapy for HER2-positive Locally Recurrent/metastatic Breast Cancer (Lr/mbc)
EUROPEAN JOURNAL OF CANCER（2015）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined